Clinical researchers call this the surrogate endpoint problem. It’s time consuming and expensive to check whether a drug improves average life span, because in order to record someone’s life span you have to wait for them to die. HDL level is the surrogate endpoint, the easy-to-check biomarker that’s supposed to stand in for “long life with no heart attack.” But the correlation between HDL and absence of heart attack might not indicate any causal link.
